Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice

British Journal of Pharmacology

Volumn 172, Issue 7, 2015, Pages 1700-1712

  Crowe, Molly S ^a   Leishman, Emma ^b   Banks, Matthew L ^c   Gujjar, Ramesh ^d   Mahadevan, Anu ^d   Bradshaw, Heather B ^b   Kinsey, Steven G ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d ORGANIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ACYLGLYCEROL LIPASE; ACYLGLYCEROL LIPASE INHIBITOR; DICLOFENAC; KETOPROFEN; KML 29; PROSTAGLANDIN SYNTHASE; RIMONABANT; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; ANALGESIC AGENT; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; FATTY ACID; ICOSANOID; PIPERIDINE DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ELECTROSPRAY; ENZYME INHIBITION; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMBINATION DRUG THERAPY; HYPERALGESIA; METABOLISM; NEURALGIA; SPINAL CORD;

ANALGESICS; ANIMALS; BENZODIOXOLES; CANNABINOID RECEPTOR ANTAGONISTS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EICOSANOIDS; ENDOCANNABINOIDS; FATTY ACIDS; HYPERALGESIA; MALE; MICE, INBRED C57BL; MONOACYLGLYCEROL LIPASES; NEURALGIA; PIPERIDINES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SPINAL CORD;

EID: 84924860926     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13012     Document Type: Article

References (58)

1. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. (2009). Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16: 411-420.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
5. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. (2006). EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13: 1153-1169.
6. Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, et al. (2004). Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41: 849-857.
7. Benett GJ, Xie YK, (1988). A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33: 87-107.
8. Bertolacci L, Romeo E, Veronesi M, Magotti P, Albani C, Dionisi M, et al. (2013). A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase. J Am Chem Soc 135: 22-25.
9. Blankman JL, Simon GM, Cravatt BF, (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14: 1347-1356.
10. Bradshaw HB, Rimmerman N, Hu SS-J, Benton VM, Stuart JM, Masuda K, et al. (2009). The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem 10: 14.
11. Chaplan SR, Pogrel JW, Yaksh TL, (1994). Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 269: 1117-1123.
12. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM, (1994). Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 59: 369-376.
13. Cipriano M, Björklund E, Wilson AA, Congiu C, Onnis V, Fowler CJ, (2013). Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen. Eur J Pharmacol 720: 383-390.
14. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB, (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87.
15. Decosterd I, Woolf CJ, (2000). Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87: 149-158.
16. Fowler CJ, Tiger G, Stenstro A, (1997). Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J Pharmacol Exp Ther 283: 729-734.
17. Fowler CJ, Janson U, Johnson RM, Wahlström G, Stenström A, Norström K, et al. (1999). Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Arch Biochem Biophys 362: 191-196.
18. Grim TW, Ghosh S, Hsu K-L, Cravatt BF, Kinsey SG, Lichtman AH, (2014). Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models. Pharmacol Biochem Behav 124: 405-411.
19. Guindon J, Beaulieu P, (2006). Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50: 814-823.
20. Guindon J, Walczak JS, Beaulieu P, (2007). Recent advances in the pharmacological management of pain. Drugs 67: 2121-2133.
21. Holt S, Paylor B, Boldrup L, Alajakku K, Vandevoorde S, Sundström A, et al. (2007). Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol 565: 26-36.
22. Huggins JP, Smart TS, Langman S, Taylor L, Young T, (2012). An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153: 1837-1846.
23. Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, et al. (2014). In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171: 1392-1407.
24. Jensen MP, Chodroff MJ, Dworkin RH, (2007). The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 68: 1178-1182.
25. Karashima Y, Talavera K, Everaerts W, Janssens A, Kwan KY, Vennekens R, et al. (2009). TRPA1 acts as a cold sensor in vitro and in vivo. Proc Natl Acad Sci U S A 106: 1273-1278.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
27. Kinsey SG, Cole EC, (2013). Acute Δ(9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice. Eur J Pharmacol 715: 111-116.
28. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, et al. (2009). Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330: 902-910.
29. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH, (2010). Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynia effects in mice through distinct cannabinoid receptor mechanisms. J Pain 11: 1420-1428.
30. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH, (2011). Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98: 21-27.
31. Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, et al. (2013). Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345: 492-501.
32. La Rana G, Russo RC, D'Agostino G, Sasso O, Raso GM, Iacono A, et al. (2008). AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: role for cannabinoid receptors. Neuropharmacology 54: 521-529.
33. Lichtman AH, Shelton CC, Advani T, Cravatt BF, (2004). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109: 319-327.
34. Lim G, Sung B, Ji RR, Mao J, (2003). Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105: 275-283.
35. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
36. McGettigan P, Henry D, (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8: e1001098.
37. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. McMahon SB, Cafferty WB, Marchand F, (2005). Immune and glial cell factors as pain mediators and modulators. Exp Neurol 192: 444-462.
39. Musumba C, Pritchard DM, Pirmohamed M, (2009). Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther 30: 517-531.
40. Naidu PS, Booker L, Cravatt BF, Lichtman AH, (2009). Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 329: 48-56.
41. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, et al. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334: 809-813.
42. Ong HT, Ong LM, Tan TE, Chean KY, (2013). Cardiovascular effects of common analgesics. Med J Malaysia 68: 189-194.
43. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
44. Pinto CE, Moura E, Serrão MP, Martins MJ, Vieira-Coelho MA, (2010). Effect of (-)-Delta(9)-tetrahydrocannabinoid on the hepatic redox state of mice. Braz J Med Biol Res 43: 325-329.
45. Raffa RB, (2001). Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther 26: 257-264.
46. Rouzer CA, Marnett LJ, (2009). Cyclooxygenases: structural and functional insights. J Lipid Res 50 (Suppl.): S29-S34.
47. Russo RC, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, et al. (2007). The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322: 236-242.
48. Sasso O, Bertorelli R, Bandiera T, Scarpelli R, Colombano G, Armirotti A, et al. (2012). Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol Res 65: 553-563.
49. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13: 1113-1119.
50. Sofaer-Bennett B, Walker J, Moore A, Lamberty J, Thorp T, O'Dwyer J, (2007). The social consequences for older people of neuropathic pain: a qualitative study. Pain Med 8: 263-270.
51. Starowicz K, Makuch W, Osikowicz M, Piscitelli F, Petrosino S, Di Marzo V, et al. (2012). Spinal anandamide produces analgesia in neuropathic rats: possible CB1- and TRPV1-mediated mechanisms. Neuropharmacology 62: 1746-1755.
52. Stuart JM, Paris JJ, Frye C, Bradshaw HB, (2013). Brain levels of prostaglandins, endocannabinoids, and related lipids are affected by mating strategies. Int J Endocrinol 2013: 436252.
53. Tallarida RJ, (2006). An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319: 1-7.
54. Tallarida RJ, (2011). Quantitative methods for assessing drug synergism. Genes Cancer 2: 1003-1008.
55. Torrance N, Smith BH, Bennett MI, Lee AJ, (2006). The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 7: 281-289.
56. Trafton JA, Oliva EM, Horst DA, Minkel JD, Humphreys K, (2004). Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment. Drug Alcohol Depend 73: 23-31.
57. Viegas A, Manso J, Corvo MC, Marques MM, Cabrita EJ, (2011). Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR. J Med Chem 54: 8555-8562.
58. Xing H, Chen M, Ling J, Tan W, Gu JG, (2007). TRPM8 mechanism of cold allodynia after chronic nerve injury. J Neurosci 27: 13680-13690.